WuXi PharmaTech (Cayman) Inc. will discontinue its U.S. biologics manufacturing operations at its Philadelphia facility as of December 31, 2008, resulting in the elimination of approximately 100 positions. The company plans to expand biologics testing, cell banking and cell therapy services at the facility.     WuXi anticipates biologics manufacturing revenues will be less than 4% of total expected annual revenue in 2008. In 2009, the company expects cost savings of approximately $10 million ...